

Marie Boyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9153984/publications.pdf>

Version: 2024-02-01

39
papers

1,222
citations

331538

21
h-index

360920

35
g-index

40
all docs

40
docs citations

40
times ranked

1634
citing authors

#	ARTICLE	IF	CITATIONS
1	Determining the prognostic significance of IKK $\hat{\pm}$ in prostate cancer. <i>Prostate</i> , 2020, 80, 1188-1202.	1.2	5
2	Plasma Metabolomics Identifies Lipid and Amino Acid Markers of Weight Loss in Patients with Upper Gastrointestinal Cancer. <i>Cancers</i> , 2019, 11, 1594.	1.7	19
3	6â€...Parallel assessment of cell viability in cardiac and cancer cells following treatment with sunitinib. , 2018, , .		0
4	Untargeted Metabolomics Profiling of an 80.5 km Simulated Treadmill Ultramarathon. <i>Metabolites</i> , 2018, 8, 14.	1.3	30
5	Lysosomotropism depends on glucose: a chloroquine resistance mechanism. <i>Cell Death and Disease</i> , 2017, 8, e3014-e3014.	2.7	37
6	Inhibitory Kappa B Kinase $\hat{\pm}$ (IKK $\hat{\pm}$) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7043-7066.	2.9	23
7	Principles of Molecular Targeting for Radionuclide Therapy. , 2017, , 35-65.		1
8	Transitioning from multi-phase to single-phase microfluidics for long-term culture and treatment of multicellular spheroids. <i>Lab on A Chip</i> , 2016, 16, 3548-3557.	3.1	33
9	Emulsion technologies for multicellular tumour spheroid radiation assays. <i>Analyst, The</i> , 2016, 141, 100-110.	1.7	62
10	Principles of Molecular Targeting for Radionuclide Therapy. , 2016, , 1-31.		0
11	New Sulphated Flavonoids from <i>Wissadula periplocifolia</i> (L.) C. Presl (Malvaceae). <i>Molecules</i> , 2015, 20, 20161-20172.	1.7	47
12	Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8683-8693.	2.9	50
13	Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species. <i>EJNMMI Research</i> , 2013, 3, 73.	1.1	8
14	Gamma Irradiation and Targeted Radionuclides Enhance the Expression of the Noradrenaline Transporter Transgene Controlled by the Radio-Inducible p21WAF1/CIP1 Promoter. <i>Radiation Research</i> , 2013, 179, 282.	0.7	3
15	The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells. <i>Journal of Nuclear Medicine</i> , 2013, 54, 953-960.	2.8	71
16	In Vivo Evaluation of a Cancer Therapy Strategy Combining HSV1716-Mediated Oncolysis with Gene Transfer and Targeted Radiotherapy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 647-654.	2.8	16
17	Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of ¹³¹ I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1146-1154.	2.8	22
18	Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 334-344.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Deletion of the Dual Specific Phosphatase-4 (DUSP-4) Gene Reveals an Essential Non-redundant Role for MAP Kinase Phosphatase-2 (MKP-2) in Proliferation and Cell Survival. <i>Journal of Biological Chemistry</i> , 2011, 286, 12933-12943.	1.6	49
20	Radiation quality-dependent bystander effects elicited by targeted radionuclides. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 951-958.	1.2	36
21	Comparison of High-Specific-Activity Ultratrace ¹²³ I-MIBG and Carrier-Added ¹²³ I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 299-308.	0.7	67
22	Preclinical Evaluation of an ¹³¹ I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 4045-4053.	0.4	48
23	Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy. <i>Nuclear Medicine and Biology</i> , 2008, 35, S9-S20.	0.3	20
24	A Transfectant Mosaic Xenograft Model for Evaluation of Targeted Radiotherapy in Combination with Gene Therapy In Vivo. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1519-1526.	2.8	12
25	Microsatellite analysis for determination of the mutagenicity of extremely low-frequency electromagnetic fields and ionising radiation in vitro. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2007, 626, 34-41.	0.9	40
26	Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase. <i>Journal of Gene Medicine</i> , 2006, 8, 557-565.	1.4	21
27	Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1007-15.	2.8	101
28	Application of Targeted Radiotherapy/Gene Therapy to Bladder Cancer Cell Lines. <i>European Urology</i> , 2005, 47, 250-256.	0.9	13
29	[¹³¹ I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter. <i>Clinical Cancer Research</i> , 2005, 11, 7929-7937.	3.2	61
30	[¹³¹ I]MIBG and topotecan: A rationale for combination therapy for neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 221-227.	3.2	26
31	Gene manipulation to enhance MIBG-targeted radionuclide therapy. <i>Nuclear Medicine and Biology</i> , 2005, 32, 749-753.	0.3	7
32	Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma. <i>Medicinal Chemistry</i> , 2005, 1, 611-618.	0.7	9
33	An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. <i>Journal of Gene Medicine</i> , 2004, 6, 937-947.	1.4	57
34	Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [¹³¹ I]MIBG and clonogenic cell kill. <i>Oncogene</i> , 2001, 20, 7804-7808.	2.6	35
35	Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: Effect on clonogenicity in both two- and three-dimensional models. <i>Cancer Gene Therapy</i> , 2000, 7, 1529-1536.	2.2	54
36	A human BRCA1 gene knockout. <i>Nature</i> , 1995, 375, 541-542.	13.7	91

#	ARTICLE	IF	CITATIONS
37	The detailed characterisation of a 400 kb cosmid walk in the BRCA1 region: identification and localisation of 10 genes including a dual-specificity phosphatase. Human Molecular Genetics, 1994, 3, 1927-1934.	1.4	17
38	Screening for molecular pathologies in Lesch-Nyhan syndrome. Human Mutation, 1993, 2, 127-130.	1.1	16
39	Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. , 0, .		1